FIG 5.

Efficacy for anti-ClfA MAb/MEDI4893* BiSAbs in i.v. bacteremia. BALB/c mice (n = 10) were passively immunized i.p. with SAR114/MEDI4893* BiS₂, BiS₃, or an SAR114-MEDI4893* combination at the indicated concentrations and were i.v. infected 24 h later with the LD₉₀ of SF8300 (6e7 CFU) (A) and 3049057 (5e7 CFU) (B). Protective efficacy for 11H10-MEDI4893* BiS₂, BiS₃, or 11H10-MEDI4893* MAbs was evaluated against SF8300 (C) or 3049057 (D) challenge. Survival was monitored for 2 weeks. Results were analyzed with a log rank (Mantel-Cox) test. Statistical analysis of results compared to those for c-IgG were considered statistically different at a P value of <0.05 and are indicated with an asterisk. Data are representative of three independent experiments.